Royalty Pharma (RPRX) is down 4.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The catalyst is not fully clear, but the move appears more tied to market conditions than to a fresh company-specific setback. Royalty Pharma’s most recent update was positive, so today’s decline could be because stronger U.S. jobs data pushed Treasury yields higher and made rate-sensitive healthcare and cash-flow valuation stories less attractive.
Details:
Sources:
Royalty Pharma, SEC, AP News
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- CHRISTOPHER HITE (EVP & Chairman, Partnering) has made 0 purchases and 7 sales selling 380,000 shares for an estimated $21,501,997.
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 9 sales selling 179,774 shares for an estimated $9,119,008.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 4 sales selling 45,565 shares for an estimated $2,458,495.
- GREGORY NORDEN sold 3,045 shares for an estimated $161,385
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RPRX Hedge Fund Activity
We have seen 386 institutional investors add shares of $RPRX stock to their portfolio, and 255 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 9,259,396 shares (+478.7%) to their portfolio in Q2 2026, for an estimated $519,174,333
- BAILLIE GIFFORD & CO removed 6,993,190 shares (-41.1%) from their portfolio in Q2 2026, for an estimated $392,108,163
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,980,633 shares (-66.6%) from their portfolio in Q2 2026, for an estimated $279,264,092
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,092,313 shares (-99.9%) from their portfolio in Q2 2026, for an estimated $173,385,989
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,083,528 shares (+inf%) to their portfolio in Q2 2026, for an estimated $172,893,414
- CAPITAL ADVISOR NETWORK LLC removed 3,030,974 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $169,946,712
- CITADEL ADVISORS LLC removed 2,592,796 shares (-49.2%) from their portfolio in Q1 2026, for an estimated $123,144,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 05/07/2026
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 4 analysts offer price targets for $RPRX in the last 6 months, with a median target of $60.5.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $58.0 on 05/07/2026
- Geoff Meacham from Citigroup set a target price of $66.0 on 05/07/2026
- Ashwani Verma from UBS set a target price of $57.0 on 04/21/2026
- Terence Flynn from Morgan Stanley set a target price of $63.0 on 04/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
